3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
29
Rectal Neoplasms
8
Colonic Neoplasms
7
Carcinoma, Hepatocellular
7
Cholangiocarcinoma
5
Stomach Neoplasms
4
Neoplasm Metastasis
4
Neoplasms
3
Biliary Tract Neoplasms
3
Adenocarcinoma Of Esophagus
3
Ovarian Neoplasms
2
Gastrointestinal Neoplasms
2
Gallbladder Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Solid Tumors
1
Recurrence
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Lung Neoplasms
1
Locally Advanced Rectal Cancer
1
Locally Advanced Colorectal Carcinoma
1
Liver Neoplasms
1
Gastroesophageal Junction Adenocarcinoma
1
Gastroesophageal Adenocarcinoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Endometrial Neoplasms
1
Disease Progression
1
Colorectal Cancer Metastatic
1
Interventions
Nivolumab
3
Cisplatin
3
capivasertib
2
Gemcitabine
2
Carboplatin
2
tivozanib
1
regorafenib
1
niraparib
1
neratinib
1
lutetium Lu 177 dotatate
1
fludarabine phosphate
1
fludarabine
1
encorafenib
1
durvalumab
1
copanlisib
1
cemiplimab
1
axicabtagene ciloleucel
1
avasopasem manganese
1
Valproic Acid
1
Thioctic Acid
1
Taxes
1
Receptors, Interleukin-6
1
Radiotherapy
1
Radiosurgery
1
RNA-Seq
1
Pemetrexed
1
Paclitaxel
1
Oxaliplatin
1
Multiparametric Magnetic Resonance Imaging
1
Leucovorin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease Progression
×
Folfox protocol
×
1 year
×
Clear all
NCT05712356
2026-05-26
BOLSTER
Lisata Therapeutics, Inc.
Phase 2
Terminated
66 enrolled
12 charts